semaglutide vs tirzepatide vs retatrutide Weight loss with retatrutide1, tirazepatide2, and semaglutide3 compared Semaglutide vs. Tirzepatide vs. Retatrutide

7 Summary and prospect NAFLD has emerged as the leading cause of chronic liver disease worldwide

Treatment plans do vary, so we will advise on this at consultation, after any testing and discussion of your individual requirements

Thyroid concerns exist for GLP-1 agonists due to findings in rodent studies showing C-cell hyperplasia and medullary thyroid carcinoma

Collectively, it may be hypothesized that obesity induces feedback inhibition of pituitary GH secretion by increasing non-fasting serum FFA levels and the associated insulin resistance that causes compensatory intra-portal hyperinsulinemia and IGFBP-1 suppression, with the net result being low GH and normal IGF-I levels